Psychedelic Stocks

New Study Documents Ayahuasca’s Common Psychological, Physical Side Effects

Ayahuasca is a psychedelic brew that is usually made from the Psychotria viridis and  Banisteriopsis caapi plants. The psychedelic has an incredibly long history in South America, with ancient Amazonian tribes using it for religious and spiritual purposes centuries ago. Even though ayahuasca is still used for religious and spiritual reasons by certain communities in Brazil and North America, recent research into psychedelics has also revealed that it has medical applications.

Studies have found that ayahuasca may be able to aid in the treatment of certain psychiatric disorders and addictions, but most researchers agree that more analysis is needed to increase knowledge of the psychedelic’s potential health benefits as well as its side effects.

With the world in the midst of a “psychedelic renaissance,” a period that has been characterized by significant investment in psychedelic research, more and more researchers are carrying out such studies.

A recent study on the psychoactive South American drink sought to determine if consuming the drink can result in any side effects, a facet of the psychedelic that has received relatively little attention. The study, whose findings were reported in the “PLOS Global Public Healthjournal, ran from 2017 to 2019 and involved more than 10,000 participants across some 50 countries.

A reported 47% of the respondents were Brazilian while Europe and North America accounted for 24% and 15% of the participant pool. Respondents filled out an online questionnaire and detailed the side effects they experienced after consuming ayahuasca.  Nausea and vomiting were by far the most common side effects at 62% followed by headaches at 17% and abdominal pain at 13%. At least 2% of the respondents had to receive medical attention due to these physical side effects.

On the mental side of things, 42% reported emotional-cognitive side effects such as disturbed thoughts and nightmares while 38% said that they experienced altered perception after their ayahuasca session.

Older people, individuals with more experience using the psychedelic brew, those with existing health conditions or a past alcohol-use disorder were more likely to report physical symptoms. Respondents who used ayahuasca unsupervised also reported experiencing physical side effects in higher numbers.

On the other hand, the mental or cognitive side effects were more likely to impact individuals with lower lifetime use of ayahuasca and those with previous anxiety issues. Traditionally, such side effects are seen as part of the psychedelic experience, with the cognitive effects being central to spiritual growth and physical symptoms such as vomiting seen as a form of purging.

However, many psychedelics startups such as Compass Pathways PLC (NASDAQ: CMPS) are looking to come up with psychedelics-based formulations that minimize the side effects of these drugs while maximizing the benefits.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

6 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago